Diabetic Foot Ulcer Treatment Market Size, Share & Industry Analysis, By Ulcer Type (Neuropathic Ulcer, Ischemic Ulcers, and Neuro-Ischemic Ulcer), By Product (Wound-care Dressings {Antimicrobial Dressings, Foam Dressings, Film Dressings, Alginate Dressings, and Other Dressings}, Wound-care Devices {Negative Pressure Wound Therapy (NPWT), Ultrasound Therapy, and Others}, Active Therapies {Skin Grafts & Substitutes, and Others), By End User (Hospitals, Clinics, Ambulatory Surgical Centers, and Homecare Settings) and Regional Forecast, 2024-2032

The global diabetic foot ulcer treatment market size was valued at USD 8.33 billion in 2023. The market is expected to grow from USD 8.83 billion in 2024 to USD 14.37 billion by 2032, exhibiting a CAGR of 6.3% during the forecast period.

Diabetic foot ulcers (DFUs) are the wounds that develop in patients with type 1 and type 2 diabetes. DFUs are common complications of diabetes characterized by non-healing wounds typically located on the feet, which can lead to severe infections and, in extreme cases, amputation. Diabetic foot ulcer care comprises a wide range of products, including advanced wound dressings such as antimicrobials, hydrogel, and others, devices such as negative pressure wound therapy (NPWT), hyperbaric oxygen therapy (HBOT), and active therapies such as skin graft substitutes. Supportive products such as offloading devices are also used to reduce pressure on the ulcer.

Furthermore, the increasing prevalence of diabetic foot ulcers among the diabetic population is expected to boost the adoption of DFU treatment products and thus, propel the growth of the market.

• For instance, according to the 2023 article published by JAMA Network, it was reported that diabetic foot ulcers affect about 18.6 million people worldwide and 1.6 million in the U.S. annually.

Additionally, severe complications associated with DFU lead to early diagnosis and treatment of DFU and thus boost the growth of the market. In addition, rising initiatives, such as collaborations and investments by key players and increasing research and development activities to launch advanced products for diabetic foot ulcer treatment, are expected to propel the market's growth during the forecast period.

• For instance, in March 2024, researchers from the University of Sheffield and the University of South Australia conducted a study on plasma-activated hydrogel dressings for tackling antibiotic-resistant pathogens during the treatment of diabetic foot ulcers and internal wounds. Such initiatives are expected to propel market growth.

The COVID-19 pandemic negatively impacted the global market. The sudden rise in the number of COVID-19 cases shifted the healthcare focus to improving the pandemic situation. This led to decreased patient hospital visits during the pandemic for diabetic foot ulcer treatment. This factor was one of the crucial factors responsible for the decline of growth in the market.

However, due to the pandemic restrictions, several medical organizations issued guidelines for managing patients with hard-to-heal wounds to promote wound care management. They recommended the use of new products for at-home chronic care and the adoption of telemedicine for consultation.

Additionally, a decline in the revenue of key players of these devices was observed during that period. However, the ease of COVID-19 guidelines and the resumption of hospital visits for DFU treatment improved the market situation in late 2021. Moreover, in 2022, the market returned to pre-pandemic levels, supported by increasing patient visits and treatment.

Furthermore, the increasing number of product launches by key players, rising research activities, and reimbursement policies by various countries' governments led to a rebound of the global market to pre-pandemic levels in 2023.

Diabetic Foot Ulcer Treatment Market Trends

Shift from Traditional to Advanced Wound Management Products to Promote Market Growth

In recent years, the global diabetic foot ulcers treatment market size has shifted from traditional wound care to advanced wound management products. Advanced wound care dressings are designed to promote faster and more effective wound healing. Products such as hydrocolloids, hydrogels, antimicrobial dressings, and foam dressings are engineered to maintain an optimal moisture balance, thus helping reduce wound healing time and control infections. Such benefits have shifted from gauze and other traditional wound dressings to more innovative ones.

• For instance, according to an article published by Wound Management & Prevention in 2022, the demand for advanced wound care products will continue to grow as the population older than 65 years is projected to increase by 25.0% by 2060.

Furthermore, there are increasing research and development activities by key players to launch advanced products with established clinical efficiency to expand diabetic foot ulcer treatment product offerings across the globe. This is expected to propel the adoption of DFU treatment products and foster market growth during the forecast period.

Diabetic Foot Ulcer Treatment Market Growth Factors

Rising Prevalence of Diabetic Foot Ulcer to Drive the Demand for Treatment

The growing prevalence of diabetes worldwide is the leading factor contributing to the rising number of diabetic foot ulcer cases, which is a major complication associated with diabetes.

The rising geriatric population, lifestyle modification, and obesity are key factors associated with the growing prevalence of diabetes worldwide. Additionally, various clinical studies demonstrate that there is a significantly higher probability of foot ulcers in a diabetic person compared to a non-diabetic patient.

• For instance, according to an article published by the International Wound Journal in 2023, the prevalence of diabetic foot ulcers is 6.3% as per the rare studies investigating its global epidemiology. Hence, the increasing prevalence is expected to boost the demand for treatment, resulting in the growing adoption of wound care products.

Moreover, DFUs are chronic and severe conditions that require long-term management to prevent complications such as infections and amputations. Thus, increasing awareness among patients and healthcare providers aimed to expand the adoption of DFU treatment products and propel the growth of the global diabetic foot ulcer treatment market.

Technological Advancements in Diabetic Foot Ulcer Treatment to Propel the Growth of the Market

In recent years, the increasing complications associated with diabetic foot ulcers increased the need for advanced wound care products for rapid healing and prevent infections. Additionally, increasing research and development initiatives by key market players to launch compact and convenient devices for DFU treatment is expected to propel the diabetic foot ulcer treatment market growth.

• For instance, in April 2024, Smith+Nephew launched the RENASYS EDGE NPWT system, a lightweight, compact device designed for home care used to treat chronic wounds, including diabetic foot ulcers. Such product launches promote the segment's growth during the forecast period.

Furthermore, the increasing application of bioactive therapies such as skin grafting growth factors for treating wounds such as diabetic foot ulcers is increasing the adoption of these treatments for rapid wound healing, thus boosting market growth.

RESTRAINING FACTORS

High Cost of Treatment and Longer Duration of Recovery Period Restricts the Market Growth

Despite the various benefits associated with treatment products for diabetic foot ulcers, their high cost hampers their adoption and decreases market growth. The longer healing time of wounds and higher changing frequencies of the products exert a huge economic cost burden on both the patients and the healthcare systems in developed and emerging countries.

• For instance, in 2023, according to an article published by the Journal of Wound Care, it was reported that a stage 4 diabetic foot ulcer can take up to a mean of 190 days to heal. Such a longer duration to repair a wound negatively impacts the patients and caregivers.

However, many developed countries are implementing reimbursement policies for DFU treatment, which are expected to maintain the position of the market during the forecast period.

Diabetic Foot Ulcer Treatment Market Segmentation Analysis

By Ulcer Type Analysis

Neuro-Ischemic Segment Dominated due to Rising Prevalence of Neuro-Ischemic Ulcers

Regarding ulcer type, the global market is segmented into neuro-ischemic, neuropathic, and ischemic ulcers.

The neuro-ischemic ulcers segment held the highest portion of the global diabetic foot ulcer treatment market share in 2023. Neuro-ischemic foot ulcers occur in people with both peripheral neuropathy and ischemia resulting from peripheral artery disease. These ulcers are least challenging to heal without intervention, and if infected, they pose a risk of amputation.

The dominant share is attributed to high prevalence, which increases the adoption of DFU treatment products, thus boosting the market's growth.

• According to an article published by Sage Journal in 2023, a study was performed at Dr. Kariadi General Hospital, Indonesia, involving 1,429 diabetic foot patients to determine the disease burden regarding the clinical profile and outcome of diabetic foot ulcer (DFU) admissions. It was found that around 29.9% of registered patients were suffering from neuro-ischemic ulcers in that patient population. Such a large number of cases associated with neuro-ischemic ulcers promotes the adoption of DFU treatment products and is expected to boost the segment's growth.

Furthermore, neuropathic ulcers held a substantial portion of the market and are expected to grow during the forecast period. The neuropathic ulcer occurs due to motor and sensory nerve damage, leading to muscle wasting and, eventually, foot deformities.

Moreover, ischemic ulcers held a notable share of the market, owing to the rising cases of peripheral artery diseases (PAD) in diabetic patients, as ischemia in the form of PAD is a significant contributor to the burden of the diabetic foot.

• For instance, in August 2023, according to the data published in the Journal of Indian College of Cardiology, the prevalence of PAD varies from 5.0% to 25.0% in the Indian setting, and with about 50.0% of diabetic foot patients predicted to have PAD. Moreover, it impairs the healing of ulcers and increases the risk of foot amputations. Such conditions associated with PAD promote early intervention and adoption of diabetic foot ulcer treatment products, thus propelling market growth.

By Product Analysis

Growing Initiatives by Key Players and Product Launches Led to Wound-Care Dressings Segment Dominance 

Based on product, the market is segmented into wound-care dressings, devices, and active therapies.

The wound-care dressings segment held the largest market share in 2023 and is further divided into antimicrobial dressings, foam dressings, film dressings, alginate dressings, hydrogel dressings, and other dressings. The segment's growth is augmented by the benefits associated with the dressings for treating DFU. Wound care dressings are a more convenient option as they are easier to apply and remove and are available in various types. They effectively manage wound exudate and maintain a moist environment, thus promoting faster wound healing.

Additionally, the increasing research and development activities by key players to launch advanced wound-care dressings for the treatment of DFU are propelling the growth of the segment in the market.

• For instance, in December 2023, Varco Leg Care launched Ulsr Soothe Max, designed to treat individuals with foot ulcers, including varicose vein ulcers and diabetic foot ulcers.

The wound-care devices segment holds a substantial market share and is expected to grow with a steady CAGR during the forecast period. The wound-care devices are divided into negative pressure wound therapy (NPWT), ultrasound therapy, hyperbaric oxygen therapy (HBOT), and others.

The segment's growth is attributed to increasing product launches by key players and rising awareness programs for wound-care devices for treating wounds.

• For instance, in May 2023, CutisCare launched its third annual Hyperbaric Aware national campaign to elevate awareness of hyperbaric oxygen therapy (HBOT) and promoted the advantages of this therapy to heal chronic wounds, including DFUs. Such awareness programs encourage the adoption of these devices in the market.

Moreover, the active therapies segment held a notable market share and is expected to grow at the highest CAGR during the forecast period. It is attributed to robust efforts by key players in the market to showcase the advantages of active therapies for treating DFU.

• For instance, in November 2022, Biocomposites hosted an Infection Management Symposium at the Wounds UK Annual Conference, highlighting a comprehensive framework and toolkit for podiatrists treating diabetic foot infections. It also demonstrated that STIMULAN can effectively release antibiotics at therapeutic levels when placed in foot wounds after debridement. Such programs promote active therapies and boost the growth of the segment.

By End User Analysis

Increasing Healthcare Expenditure and Regulatory Approvals for Homecare-based Products Expected To Propel Segment Growth

Based on end user, the global market is segmented into hospitals, clinics, ambulatory surgical centers, and home care settings.  

The hospital segment dominated the global market in 2023. The highest share of the segment is due to the facilities provided by the hospitals and the higher preference of patients toward hospitals for wound care. The increasing number of hospitalizations of patients and the demand for advanced diabetic wound care with skilled professionals boosted the segment's growth.

Additionally, increasing healthcare expenditure and reimbursement policies for the treatment of DFU is propelling the adoption of diabetic wound treatment products and eventually increasing the segment's growth.

• For instance, according to the data published by the National Institute for Health and Care Research (NIHR) in 2019, over 100,000 people in the U.K. are estimated to suffer from DFU at any time, and National Health Services (NHS) is ready to spend around USD 1.24 billion to treat DFU. Such initiatives by health authorities boost the adoption of the products and thus propel the growth of the segment in the market.

The clinics segment held a significant portion of the market, driven by advanced and specialized service offerings with state-of-the-art facilities for DFU treatment.

Furthermore, the ambulatory surgical centers (ASCs) segment is projected to expand at a significant CAGR. The segment's growth is due to the growing number of ASCs in developed regions such as the U.S.  and advanced chronic wound care facilities. For instance, according to the Ambulatory Surgery Center Association, there are 6,200 Medicare-certified ASCs in the U.S. Such substantial growth of the ASCs is expected to boost the development of the segment in the market.

On the other hand, home care settings held a notable market share. The increasing number of product launches by key players for home-based treatment of diabetic foot ulcers is expected to propel the segment's growth during the forecast period.

• For instance, in March 2022, Advanced Oxygen Therapy Inc. (AOTI) received approval from the Chinese National Medical Products Administration (NMPA) for their unique cyclically pressurized Topical Wound Oxygen (TWO2) therapy. This globally patented TWO2 homecare therapy provides more durable, complete DFU healing, showcasing efforts by key companies to boost the growth of the segment in the market.

REGIONAL INSIGHTS

The market is segmented geographically into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America held a dominant position in the global market, with a market size valued at USD 3.27 billion in 2023. The region's dominance is attributed to the increasing prevalence of diabetic foot ulcers, and rising awareness among people for the early treatment of chronic wounds is expected to propel the adoption of DFU treatment products in the region. Additionally, the increasing collaborations and rising awareness programs in the region to launch advanced treatments for DFU are expected to boost the region's growth in the market.

• For instance, in June 2023, Siksika Health Services (SHS) partnered with Orpyx Medical Technologies and GMAK Consulting to launch a second pilot program focused on enhancing foot health and reducing the risk of diabetic foot ulcers (DFUs) among individuals from Siksika Nation with type 2 diabetes. Such collaborative activities among key players lead to the early intervention and adoption of DFU treatment products and thus propel the region's growth.

Additionally, the presence of advanced healthcare infrastructure, with well-versed reimbursement policies for treating the disease in the region, is expected to boost the market growth in the region.

On the other hand, Europe held the second-largest share of the global market in 2023. The region's significant share in the market is due to the rising prevalence of diabetes and diabetic foot ulcers associated with it. Additionally, the presence of key players in the market in the region with advanced product offerings, advanced facilities, and skilled healthcare professionals is subsequently driving the growth of this region in the forecast period.

The Asia Pacific is expected to grow with the highest CAGR during the forecast period. The growth of the region is augmented by the rising geriatric population and lifestyle modification, leading to an increasing prevalence of diabetes and some cases associated with diabetic foot ulcers in the region. Additionally, increasing initiatives by key players to expand their footprint in the global diabetic foot ulcer market are expected to propel the region's growth during 2024-2032.

• For instance, in January 2022, Alkem Laboratories Ltd. launched patented 4D Bioprinting technology for treating diabetic foot ulcers in India, aimed at preventing amputations in diabetic patients at affordable rates.

Latin America and the Middle East & Africa region held a relatively low market share and are expected to grow during the forecast period due to the increasing number of DFU cases. Rising healthcare expenditure, strategic expansion by key players, and increasing regulatory approvals for treatment products in the region are expected to boost product adoption during the forecast period.

• For instance, in March 2024, Biocomposites announced that STIMULAN, a calcium matrix antibiotic carrier, was approved in Brazil. This matrix is used to heal and treat bacterial infections in diabetic wounds. Such approvals promote the growth of the region during the projected timeframe.

KEY INDUSTRY PLAYERS

Advanced Product Offerings and Robust Distribution Network by Key Players Help to Strengthen Their Market Position

The competitive landscape of the market tends to be highly fragmented. 3M, Smith+Nephew, and Mölnlycke Health Care AB are significant players in the global market share. The strong position of the companies is attributed to the presence of strong product portfolios, strong geographic presence, and rising focus toward strategic activities such as collaborations and acquisitions to advance product offerings in the market.

Additionally, increasing research and development activities by key players and rising regulatory approvals for advancing the treatment options for diabetic foot ulcers are expected to maintain the company's position in the market.

• For instance, in April 2023, 3M received U.S. FDA approval for two innovative 3M Veraflo Therapy, with 3M Veraflo Cleanse Choice Complete Dressing and 3M V.A.C. Veraflo Cleanse Choice Dressing intending to expand its product offerings. This approval helped to strengthen their product portfolio in the market.

The other prominent players include Cardinal Health, B. Braun SE, Integra LifeSciences Corporation, Essity Aktiebolag (publ), Convatec Inc., and other key players. The diversified product offerings and initiatives for research and development for launching innovative technologies and advanced products with regulatory approvals are anticipated to boost their market presence during the forecast period.

LIST OF TOP DIABETIC FOOT ULCER TREATMENT COMPANIES:

• Coloplast A/S (Denmark)


• Smith+Nephew (U.K.)


• 3M (U.S.)


• Convatec Inc. (U.S.)


• Integra LifeSciences (U.K.)


• B. Braun SE (Germany)


• Cardinal Health (U.S.)


• Mölnlycke Health Care AB (Sweden)


• Essity Aktiebolag (publ). (Sweden)

KEY INDUSTRY DEVELOPMENTS:

• April 2024: Smith+Nephew announced that the U.K. National Institute for Health and Care Excellence (NICE) reviewed the PICO Single Use Negative Pressure Wound Therapy System (sNPWT). NICE found that it provides better clinical outcomes than standard dressings to reduce the risk of surgical site infection.


• March 2023: Convatec Inc. received U.S. FDA approval for InnovaBurn placental extracellular matrix medical device. It is designed for managing complex surgical wounds and burns, including partial thickness second-degree burns, and can be used for diabetic ulcers to strengthen its product offerings.


• August 2022: 3M launched a new 3M Veraflo Cleanse Choice Complete Dressing Kit and a software upgrade for the 3M V.A.C. Ulta Therapy Unit, intending to advance the delivery of Veraflo therapy among patients.


• March 2022: Convatec Inc. acquired Triad Life Sciences Inc., intending to enter the wound biologics segment globally to advance wound care management.


• December 2021:  Essity Aktiebolag (publ). acquired Hydrofera to incorporate the company's advanced line of wound care products in the medical solutions segment.


• November 2020: SANARA MEDTECH launched antimicrobial hydrogel wound dressing called BIAKŌS Antimicrobial Wound Gel. Used for management of diabetic foot ulcers, post-surgical wounds, pressure ulcers, first and second-degree burns, grafts and donor sites..

REPORT COVERAGE

The global diabetic foot ulcer treatment market report focuses on an industry overview and market dynamics, such as the drivers, restraints, opportunities, and trends. Besides this, the global diabetic foot ulcer treatment market report market research report provides information on the economic cost burden for wound care in key countries. Furthermore, the global market analysis also focuses on the prevalence of key diseases, key industry developments, and new product launches. In addition, the impact of COVID-19 and the industry overview during the pandemic are covered in the report.

Report Scope & Segmentation

ATTRIBUTE	DETAILS
Study Period	2019-2032
Base Year	2023
Estimated Year	2024
Forecast Period	2024-2032
Historical Period	2019-2022
Unit	Value (USD billion)
Growth Rate	CAGR of 6.3% from 2024-2032
Segmentation	By  Ulcer Type Neuropathic Ulcer Ischemic Ulcers Neuro-ischemic Ulcer
By Product Wound-care Dressings Antimicrobial Dressings Foam Dressings Film Dressings Alginate Dressings Hydrogel Dressings Other Dressings Wound-care Devices Negative Pressure Wound Therapy (NPWT) Ultrasound Therapy Hyperbaric Oxygen Therapy (HBOT) Others Active Therapies Skin Grafts & Substitutes Growth Factors Others Others
By End User Hospitals Clinics Ambulatory Surgical Centers Homecare Settings
By Region North America (By Ulcer Type, By Product,  By End User, and By Country) U.S. Canada Europe (By Ulcer Type, By Product, By End User, and By Country/Sub-Region) U.K. Germany France Spain Italy Scandinavia Rest of Europe Asia Pacific (By Ulcer Type, By Product,  By End User, and By Country/Sub-Region) Japan China India Australia Southeast Asia Rest of Asia Pacific Latin America (By Ulcer Type, By Product, By End User, and By Country/Sub-Region) Brazil Mexico Rest of Latin America Middle East & Africa ( By  Ulcer Type, By Product, By End User, and By Country/Sub-Region) GCC South Africa Rest of Middle East & Africa